Hepatitis Testing Markets

Sep 1, 2017
50 Pages - Pub ID: KLI15466368
Share this report
 
Online Download $2,500
Departmental Site License (one location, 10 users) $3,500
Global Site License $5,000
Hepatitis Testing Markets

Hepatitis infection remains a significant challenge for the medical community. According to the CDC, around 2.7 million people in the United States have a chronic HCV infection or nearly 1% of the population. This report, Hepatitis Testing Markets, includes:
  • Hepatitis Immunoassay Market, 2016 - 2021
  • Hepatitis Molecular Testing Market, 2016 -2021
  • Hepatitis Point of Care Markets, 2016-2021
  • Molecular Testing Market by Type (C, B, A and Others)
  • Key Trends in the Market
  • Geographic Breakout of Market (US, ROW)
  • Company Profiles
HCV in particular is a driver of sales in this market. While HCV infections are increasingly caught and treated among baby boomers (a fact easily observable in Medicare billings), U.S. HCV incidence is also sharply increasingly among younger generations or individuals 20-39 years of age. Intravenous drug use is again the cause of rising HCV cases in this age group as well.

Molecular diagnostics is unrivaled among the IVD technologies used for infectious disease testing in terms of its performance and applicability. Microarray, next-generation sequencing and development-stage isothermal amplification methods represent promising contributions to the market space. For the time being, PCR and isothermal amplification tests represent the bulk of the market with assay development proceeding faster than ever using genomic science tools, microfluidics, machine automation, and novel forms of results detection. Immunoassays are more often used for the initial detection of hepatitis infections, but with the increasing significance of hepatitis in healthcare and the development of sophisticated antiviral therapeutics, molecular tests are becoming just as integral to clinical hepatitis treatment.
1: EXECUTIVE SUMMARY
INTRODUCTION
Figure 1-1 New Cases Hepatitis, U.S.
VIRUS TYPES
Hep A
Hep B
Hep C
Hep D
Hep E
Increased Focus on HCV
Table 1-1: New Cases, Hepatitis A, B and C - 2005 to 2014
TESTING METHODS - MOLECULAR DIAGNOSTICS
TESTING METHODS - IMMUNOASSAYS
MARKET FOR HEPATITIS TESTING
Figure 1-1: Hepatitis Testing Market, 2016 -2021
2: HEPATITIS TESTING TECHNOLOGIES AND TRENDS
Table 2-1: Selected Hepatitis Test Innovations
IMMUNOASSAYS FOR HEPATITIS
Serological antibody assays
POC Rapid Immunoassays
Enzyme Immunoassay (EIA)
Chemiluminescence immunoassay (CIA)
Recombinant immunoblot assay (RIBA)
EIA.Immunofluorescence
MOLECULAR TECHNOLOGIES
Real-Time PCR (qPCR)
Loop-Mediated Isothermal Amplification (LAMP)
3: MARKET FOR HEPATITIS DIAGNOSTICS
MARKET ANALYSIS BY PRODUCT
Immuonassay
Table 3-1: Hepatitis, Immunoassay Testing Market (United States, ROW) 2016-21
POINT OF CARE
POC Developments
Table 3-1: Hepatitis, POC Testing Market (United States, ROW) 2016-21
Molecular
Table 3-3: Molecular Hepatitis Market Breakdown 2016-2021 United States, ROW ($M)
HEPATITIS COMPETITIVE ANALYSIS
4: COMPANY PROFILES
ABBOTT DIAGNOSTICS
Table 4-1: Abbott Diagnostics Revenue (2013-2016) ($ millions)
Infectious Diseases/qPCR
BECKMAN COULTER (DANAHER)
Hep C
Hep B; A-H
BIOMÉRIEUX
Table 4-2: bioMérieux Revenue (2013-2016) ($ millions)
bioMerieux Hepatitis Tests
Molecular
Sequencing
CEPHEID (DANAHER)
Table 4-3: Cepheid Revenue (2013-2016) ($ millions)
MEDMIRA
Products
ORASURE TECHNOLOGIES
QIAGEN
Table 4-4: Qiagen Revenue (2013-2016) ($ millions)
artus
ROCHE DIAGNOSTICS
Table 4-5: Roche Diagnostics Revenue (2013-2016) ($ millions)
Molecular Diagnostics
Hepatitis Tests
SIEMENS HEALTHCARE DIAGNOSTICS
Hepatitis Tests

In this report, {{keyword[keywordTextProperty]}} appears {{keyword[keywordCountProperty]}} times. {{searchResults.STATRESULT.SUMMARY.KW[keywordTextProperty]}} appears {{searchResults.STATRESULT.SUMMARY.KW[keywordCountProperty]}} times.

We were unable to search inside this report.

Search for an exact word or phrase by placing the word or phrase in quotation marks ("market trend"). Search for different versions or tenses of a word by placing an asterisk at the end of the word (pharma*).

Please note that your term must be at least three characters long and numbers will be blocked by the # sign.